A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT ID: NCT06431373
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
371 participants
INTERVENTIONAL
2024-09-11
2028-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
NCT05523765
Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
NCT01900431
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
NCT01684345
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
NCT01138657
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
NCT00404612
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Brepocitinib PO QD
Brepocitinib PO QD
Arm 2
Placebo PO QD
Placebo PO QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brepocitinib PO QD
Brepocitinib PO QD
Placebo PO QD
Placebo PO QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
* Active uveitic disease in at least 1 eye
* Weight \> 40 kg with a body mass index ≤ 40 kg/m2
Exclusion Criteria
1. Lymphoproliferative disorder
2. active malignancy
3. cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
4. thrombosis or cerebrovascular ischemic event disease within the last 12 months
5. a high risk for herpes zoster reactivation
6. active or recent infections
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Priovant Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Bakersfield, California, United States
Clinical Trial Site
Beverly Hills, California, United States
Clinical Trial Site
Fullerton, California, United States
Clinical Trial Site
Irvine, California, United States
Clinical Trial Site
La Jolla, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Modesto, California, United States
Clinical Trial Site
Sacramento, California, United States
Clinical Trial Site
Aurora, Colorado, United States
Clinical Trial Site
Denver, Colorado, United States
Clinical Trial Site
Fort Lauderdale, Florida, United States
Clinical Trial Site
St. Petersburg, Florida, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Oak Park, Illinois, United States
Clinical Trial Site
Carmel, Indiana, United States
Clinical Trial Site
Prairie Village, Kansas, United States
Clinical Trial Site
Baltimore, Maryland, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Waltham, Massachusetts, United States
Clinical Trial Site
Ann Arbor, Michigan, United States
Clinical Trial Site
Detroit, Michigan, United States
Clinical Trial Site
Detroit, Michigan, United States
Clinical Trial Site
Minneapolis, Minnesota, United States
Clinical Trial Site
Rochester, Minnesota, United States
Clinical Trial Site
St Louis, Missouri, United States
Clinical Trial Site
Omaha, Nebraska, United States
Clinical Trial Site
Palisades Park, New Jersey, United States
NYU Langone Health
New York, New York, United States
Clinical Trial Site
Rochester, New York, United States
Clinical Trial Site
Durham, North Carolina, United States
Clinical Trial Site
Winston-Salem, North Carolina, United States
Clinical Trial Site
Cleveland, Ohio, United States
Clinical Trial Site
Cleveland, Ohio, United States
Clinical Trial Site
Columbus, Ohio, United States
Clinical Trial Site
Portland, Oregon, United States
Clinical Trial Site
Portland, Oregon, United States
Clinical Trial Site
Erie, Pennsylvania, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Greenville, South Carolina, United States
Clinical Trial Site
Nashville, Tennessee, United States
Clinical Trial Site
Austin, Texas, United States
Clinical Trial Site
Bellaire, Texas, United States
Clinical Trial Site
Dallas, Texas, United States
Clinical Trial Site
Houston, Texas, United States
Clinical Trial Site
Katy, Texas, United States
Clinical Trial Site
Plano, Texas, United States
Clinical Trial Site
Round Rock, Texas, United States
Clinical Trial Site
San Antonio, Texas, United States
Clinical Trial Site
Madison, Wisconsin, United States
Clinical Trial Site
Rosario, Santa Fe Province, Argentina
Clinical Trial Site
Buenos Aires, , Argentina
Clinical Trial Site
Buenos Aires, , Argentina
Clinical Trial Site
Buenos Aires, , Argentina
Clinical Trial Site
Buenos Aires, , Argentina
Clinical Trial Site
Sydney, New South Wales, Australia
Clinical Trial Site
East Melbourne, Victoria, Australia
Clinical Trial Site
Nedlands, Western Australia, Australia
Clinical Trial Site
Linz, , Austria
Clinical Trial Site
Leuven, VI-Brabant, Belgium
Clinical Trial Site
Prague, , Czechia
Clinical Trial Site
Mannheim, Baden-Wurttemberg, Germany
Clinical Trial Site
Bonn, North Rhine-Westphalia, Germany
Clinical Trial Site
Düsseldorf, North Rhine-Westphalia, Germany
Clinical Trial Site
Münster, North Rhine-Westphalia, Germany
Clinical Trial Site
Münster, North Rhine-Westphalia, Germany
Clinical Trial Site
Kiel, , Germany
Clinical Trial Site
Mainz, , Germany
Clinical Trial Site
Thessaloniki, , Greece
Clinical Trial Site
Pécs, Baranya, Hungary
Clinical Trial Site
Debrecen, Hajdú-Bihar, Hungary
Clinical Trial Site
Budapest, Pest County, Hungary
Clinical Trial Site
Budapest, , Hungary
Clinical Trial Site
Ashkelon, , Israel
Clinical Trial Site
Haifa, , Israel
Clinical Trial Site
Haifa, , Israel
Clinical Trial Site
Holon, , Israel
Clinical Trial Site
Jerusalem, , Israel
Clinical Trial Site
Jerusalem, , Israel
Clinical Trial Site
Kfar Saba, , Israel
Clinical Trial Site
Poria – Neve Oved, , Israel
Clinical Trial Site
Tel Aviv, , Israel
Clinical Trial Site
Tel Aviv, , Israel
Clinical Trial Site
Perugia, Umbria, Italy
Clinical Trial Site
Milan, , Italy
Clinical Trial Site
Reggio Emilia, , Italy
Clinical Trial Site
Roma, , Italy
Clinical Trial Site
Barcelona, Catalonia, Spain
Clinical Trial Site
Barcelona, , Spain
Clinical Trial Site
Madrid, , Spain
Clinical Trial Site
Madrid, , Spain
Clinical Trial Site
Valladolid, , Spain
Clinical Trial Site
London, England, United Kingdom
Clinical Trial Site
London, England, United Kingdom
Clinical Trial Site
Maidstone, Kent, United Kingdom
Clinical Trial Site
Middlesbrough, North Yorkshire, United Kingdom
Clinical Trial Site
Oxford, Oxfordshire, United Kingdom
Clinical Trial Site
Sheffield, South Yorkshire, United Kingdom
Clinical Trial Site
Birmingham, West Midlands, United Kingdom
Clinical Trial Site
Bradford, Yorkshire, United Kingdom
Clinical Trial Site
Birmingham, , United Kingdom
Clinical Trial Site
Bristol, , United Kingdom
Clinical Trial Site
Liverpool, , United Kingdom
Clinical Trial Site
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PVT-2201-303
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.